Tinengotinib

Description

Tinengotinib TT00420 is an orally active, spectrally selective small molecule kinase inhibitor targeting Aurora A/B IC50=1.2-3.3 nM , FGFR1/2/3 IC50=1.5-3.5 nM , VEGFRs, JAK1/2 and CSF1R. Tinengotinib blocks Aurora kinase-mediated cell cycle progression inducing G2/M arrest , inhibits FGFR/JNK-JUN signaling pathway and activates MEK/ERK-dependent apoptotic pathway. Tinengotinib has the activity of anti-tumor proliferation, inducing apoptosis, inhibiting angiogenesis and regulating tumor microenvironment. Tinengotinib can be used in the study of triple-negative breast cancer TNBC , gallbladder cancer and tumor immune microenvironment.